Alector, Inc. (NASDAQ:ALEC) Discusses on Alector R&D Briefing: A Review of Our PGRN Franchise and Brain Carrier Programs Transcript
Company Participants
Katie Hogan – Senior Director of Corporate Communication & Investor Relations
Sara Kenkare-Mitra – President and Head of Research & Development
Arnon Rosenthal – Co-Founder, CEO & Director
Giacomo Salvadore – Chief Medical Officer
Conference Call Participants
Pete Stavropoulos – Cantor Fitzgerald & Co., Research Division
Myles Minter – William Blair & Company L.L.C., Research Division
Thomas Shrader – BTIG, LLC, Research Division
Steven Alexopoulos – TD Cowen, Research Division
Julian Pino – Stifel, Nicolaus & Company, Incorporated, Research Division
Alec Stranahan – BofA Securities, Research Division
Graig Suvannavejh – Mizuho Securities USA LLC, Research Division
Presentation
Operator
Good morning, ladies and gentlemen, and welcome to Alector’s conference call and webcast highlighting its progranulin franchise and Alector Brain Carrier programs. [Operator Instructions]
Now I would like to turn the call over to Katie Hogan, Senior Director of Corporate Communications and Investor Relations. Please go ahead.
Katie Hogan
Senior Director of Corporate Communication & Investor Relations
Hello, everyone, and welcome to our event. Before we begin, I will go over a few housekeeping reminders. There will be a moderated question-and-answer session following prepared remarks. [Operator Instructions] The webcast replay of this event will be available tomorrow after 12:30 p.m. Eastern in the Investors section under Events and Presentations on our website, www.alector.com. I’d like to note that during this event, we’ll be making a number of forward-looking statements, and you can find our disclosure here.
Turning now to the agenda. We’ll begin with an overview from Dr. Sara Kenkare-Mitra, our President and Head of Research and Development. She’ll share Alector’s perspective on our multistage pipeline and our approach to driving value in treating neurodegeneration. Sara will then provide a review of our progranulin elevating franchise in FTD-GRN and Alzheimer’s disease, highlighting latozinemab and
#Alector #ALEC #Discusses #Alector #Briefing #Review #PGRN #Franchise #Brain #Carrier #Programs #Transcript